Cys-mc-MMAE
Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E and a linker. Cys-mc-MMAE can be used for synthesis of ADCs[1].
Product Specifications
UNSPSC
12352203
Target
Drug-Linker Conjugates for ADC
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cys-mc-mmae.html
Purity
99.85
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC[C@@H]([C@H](N(C)C([C@@H](NC([C@@H](N(C)C(CCCCCN1C(C(CC1=O)SC[C@@H](C(O)=O)N)=O)=O)C(C)C)=O)C(C)C)=O)[C@H](OC)CC(N2[C@H]([C@H](OC)[C@H](C(N[C@@H]([C@H](C3=CC=CC=C3)O)C)=O)C)CCC2)=O)C
Molecular Formula
C52H85N7O12S
Molecular Weight
1032.34
References & Citations
[1]Wang Y, et al. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety. Cancers (Basel) . 2020 Mar 21;12 (3) :744.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC403080-100 1x 100 µL
HER-2 / c-erbB-2 / neu / CD340 (ERBB2/3080), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 